S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
Log in
NASDAQ:REGN

Regeneron Pharmaceuticals Stock Forecast, Price & News

$453.19
-5.41 (-1.18 %)
(As of 02/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$448.33
Now: $453.19
$465.00
50-Day Range
$458.60
MA: $501.67
$548.20
52-Week Range
$418.01
Now: $453.19
$664.64
Volume1.12 million shs
Average Volume1.11 million shs
Market Capitalization$48.55 billion
P/E Ratio16.56
Dividend YieldN/A
Beta0.3
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and BioNTech. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Regeneron Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:REGN
CUSIP75886F10
Phone914-847-7000
Employees8,314
Year Founded1988

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.86 billion
Cash Flow$21.44 per share
Book Value$100.56 per share

Profitability

Net Income$2.12 billion

Miscellaneous

Market Cap$48.55 billion
Next Earnings Date5/4/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

2.61 out of 5 stars

Medical Sector

7th out of 1,957 stocks

Pharmaceutical Preparations Industry

3rd out of 771 stocks

Analyst Opinion: 4.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 4.4 5 -4 -3 -2 -1 -
$453.19
-5.41 (-1.18 %)
(As of 02/25/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive REGN News and Ratings via Email

Sign-up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Regeneron Pharmaceuticals (NASDAQ:REGN) Frequently Asked Questions

Is Regeneron Pharmaceuticals a buy right now?

24 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 6 hold ratings, 17 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Regeneron Pharmaceuticals stock.
View analyst ratings for Regeneron Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Regeneron Pharmaceuticals?

Wall Street analysts have given Regeneron Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Regeneron Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals saw a decline in short interest in the month of January. As of January 29th, there was short interest totaling 1,940,000 shares, a decline of 18.8% from the January 14th total of 2,390,000 shares. Based on an average daily trading volume, of 989,500 shares, the days-to-cover ratio is currently 2.0 days. Currently, 1.9% of the shares of the company are short sold.
View Regeneron Pharmaceuticals' Short Interest
.

When is Regeneron Pharmaceuticals' next earnings date?

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Regeneron Pharmaceuticals
.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) released its quarterly earnings data on Thursday, February, 4th. The biopharmaceutical company reported $9.53 earnings per share for the quarter, topping the consensus estimate of $7.11 by $2.42. The biopharmaceutical company earned $2.42 billion during the quarter, compared to analyst estimates of $2.40 billion. Regeneron Pharmaceuticals had a trailing twelve-month return on equity of 28.97% and a net margin of 38.28%. The company's quarterly revenue was up 11.7% compared to the same quarter last year. During the same period last year, the firm posted $7.50 EPS.
View Regeneron Pharmaceuticals' earnings history
.

How has Regeneron Pharmaceuticals' stock been impacted by Coronavirus?

Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, REGN stock has decreased by 2.5% and is now trading at $453.19.
View which stocks have been most impacted by COVID-19
.

How will Regeneron Pharmaceuticals' stock buyback program work?

Regeneron Pharmaceuticals declared that its Board of Directors has initiated a share buyback plan on Tuesday, November 5th 2019, which allows the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 2.9% of its shares through open market purchases. Shares buyback plans are usually a sign that the company's board of directors believes its stock is undervalued.

What price target have analysts set for REGN?

24 brokerages have issued twelve-month price targets for Regeneron Pharmaceuticals' stock. Their forecasts range from $429.00 to $800.00. On average, they anticipate Regeneron Pharmaceuticals' stock price to reach $621.15 in the next twelve months. This suggests a possible upside of 37.1% from the stock's current price.
View analysts' price targets for Regeneron Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the following people:
  • Dr. Leonard S. Schleifer, Co-Founder, Pres, CEO & Exec. Director (Age 68, Pay $4.77M)
  • Dr. George D. Yancopoulos, Co-Founder, Pres & Chief Scientific Officer & Director (Age 61, Pay $3.98M) (LinkedIn Profile)
  • Mr. Robert E. Landry Jr., Exec. VP of Fin. & CFO (Age 57, Pay $1.56M) (LinkedIn Profile)
  • Dr. Andrew J. Murphy, Exec. VP of Research (Age 63, Pay $1.29M)
  • Mr. Daniel P. Van Plew, Exec. VP and GM of Industrial Operations & Product Supply (Age 48, Pay $1.46M)
  • Ms. Patrice Gilooly, Sr. VP of Quality Assurance & Operations
  • Mr. Christopher R. Fenimore, Sr. VP, Head of Accounting & Controller (Age 50)
  • Mr. Gerald Underwood, Sr. VP of Technical Operations
  • Mr. Bob McCowan, Sr. VP of IT & Chief Information Officer
  • Justin Holko, VP of Investor Relations

What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?

423 employees have rated Regeneron Pharmaceuticals CEO Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among Regeneron Pharmaceuticals' employees.

Who are some of Regeneron Pharmaceuticals' key competitors?

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), The Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and salesforce.com (CRM).

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (10.76%), BlackRock Inc. (9.16%), Alliancebernstein L.P. (1.65%), Northern Trust Corp (1.16%), Renaissance Technologies LLC (0.85%) and Price T Rowe Associates Inc. MD (0.81%). Company insiders that own Regeneron Pharmaceuticals stock include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Marion Mccourt, Michael S Brown, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Robert E Landry and Sanofi.
View institutional ownership trends for Regeneron Pharmaceuticals
.

Which major investors are selling Regeneron Pharmaceuticals stock?

REGN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Nuveen Asset Management LLC, First Trust Advisors LP, Renaissance Technologies LLC, Bessemer Group Inc., Voloridge Investment Management LLC, Price T Rowe Associates Inc. MD, and Northern Trust Corp. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Marion Mccourt, Michael S Brown, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, and Robert E Landry.
View insider buying and selling activity for Regeneron Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Regeneron Pharmaceuticals stock?

REGN stock was acquired by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Morgan Stanley, Assenagon Asset Management S.A., Brandywine Global Investment Management LLC, Candriam Luxembourg S.C.A., NN Investment Partners Holdings N.V., Armistice Capital LLC, and Janus Henderson Group PLC.
View insider buying and selling activity for Regeneron Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $453.19.

How much money does Regeneron Pharmaceuticals make?

Regeneron Pharmaceuticals has a market capitalization of $48.55 billion and generates $7.86 billion in revenue each year. The biopharmaceutical company earns $2.12 billion in net income (profit) each year or $21.47 on an earnings per share basis.

How many employees does Regeneron Pharmaceuticals have?

Regeneron Pharmaceuticals employs 8,314 workers across the globe.

Does Regeneron Pharmaceuticals have any subsidiaries?

The following companies are subsidiares of Regeneron Pharmaceuticals: Loop Road Holdings LLC, OSMR Holdings, OSMR International, OSMR LLC, Old Saw Mill Holdings LLC, Regeneron Assurance, Regeneron Atlantic Holdings, Regeneron Belgium BVBA, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron Healthcare Solutions, Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron Spain, Regeneron UK Limited, and Rockwood Road Holdings LLC.

When was Regeneron Pharmaceuticals founded?

Regeneron Pharmaceuticals was founded in 1988.

What is Regeneron Pharmaceuticals' official website?

The official website for Regeneron Pharmaceuticals is www.regeneron.com.

Where are Regeneron Pharmaceuticals' headquarters?

Regeneron Pharmaceuticals is headquartered at 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591.

How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]


This page was last updated on 2/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.